Allogene Therapeutics Inc. (ALLO)’s Financial Results Comparing With XOMA Corporation (NASDAQ:XOMA)

Allogene Therapeutics Inc. (NASDAQ:ALLO) and XOMA Corporation (NASDAQ:XOMA) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Allogene Therapeutics Inc. N/A 0.00 211.50M 0.00 0.00
XOMA Corporation 5.30M 20.86 13.34M -1.35 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Allogene Therapeutics Inc. and XOMA Corporation.

Profitability

Table 2 demonstrates the return on equity, return on assets and net margins of Allogene Therapeutics Inc. and XOMA Corporation.

Net Margins Return on Equity Return on Assets
Allogene Therapeutics Inc. 0.00% 0% 0%
XOMA Corporation -251.70% -257.7% -25.6%

Liquidity

Allogene Therapeutics Inc.’s Current Ratio and Quick Ratio are 1.6 and 1.6 respectively. The Current Ratio and Quick Ratio of its competitor XOMA Corporation are 5.4 and 5.4 respectively. XOMA Corporation therefore has a better chance of paying off short and long-term obligations compared to Allogene Therapeutics Inc.

Analyst Recommendations

In next table is delivered Allogene Therapeutics Inc. and XOMA Corporation’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Allogene Therapeutics Inc. 0 0 2 3.00
XOMA Corporation 0 0 1 3.00

Allogene Therapeutics Inc.’s upside potential is 76.33% at a $45 consensus price target. Competitively the consensus price target of XOMA Corporation is $26, which is potential 105.05% upside. The data from earlier shows that analysts opinion suggest that XOMA Corporation seems more appealing than Allogene Therapeutics Inc.

Institutional and Insider Ownership

Allogene Therapeutics Inc. and XOMA Corporation has shares owned by institutional investors as follows: 52.3% and 56.8%. About 21.2% of Allogene Therapeutics Inc.’s share are owned by insiders. Insiders Competitively, owned 0.4% of XOMA Corporation shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Allogene Therapeutics Inc. 0.66% 5.31% 4.72% 0% 0% 18.6%
XOMA Corporation 4.62% 25.6% -3.62% -17.47% -42.96% 19.84%

For the past year Allogene Therapeutics Inc.’s stock price has smaller growth than XOMA Corporation.

Summary

XOMA Corporation beats on 6 of the 10 factors Allogene Therapeutics Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.

XOMA Corporation discovers, develops, and commercializes antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The companyÂ’s product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. Its preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has research and development collaboration and licensing agreements with Novartis AG; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.